Neuropeptidergic control of cyclic AMP accumulation in human thyroid cell.
Somatostatin (SRIF), cholecystokinin (CCK), gastrin and substance P, as single agents, do not influence baseline cellular cAMP levels in human thyroid cultures. SRIF inhibits TSH-induced cAMP accumulation in human thyroid cell, while CCK, gastrin and substance P do not modify cAMP response to TSH. Vasoactive intestinal peptide (VIP) increases cellular cAMP levels in human thyroid cultures and its effect is additive to increases produced by norepinephrine (NE) and isoproterenol (ISO). Neither SRIF nor the other tested peptides influence adrenergic and VIP-ergic cAMP stimulation.
Brandi
M L
ML
Toccafondi
R
R
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D002478:Cells, Cultured; D002766:Cholecystokinin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism*; D005755:Gastrins / Q000494:pharmacology; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology; D007700:Kinetics; D009419:Nerve Tissue Proteins / Q000494:pharmacology*; D009638:Norepinephrine / Q000494:pharmacology; D013004:Somatostatin / Q000494:pharmacology; D013373:Substance P / Q000494:pharmacology; D013961:Thyroid Gland / Q000187:drug effects / Q000378:metabolism*; D013972:Thyrotropin / Q000494:pharmacology; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology
D005755:Gastrins; D009419:Nerve Tissue Proteins; D013373:Substance P; D014660:Vasoactive Intestinal Peptide; D013004:Somatostatin; D013972:Thyrotropin; D002766:Cholecystokinin; D000242:Cyclic AMP; D007545:Isoproterenol; D015056:1-Methyl-3-isobutylxanthine; D009638:Norepinephrine